Financiere des Professionnels Fonds d investissement inc. Sells 18,948 Shares of Icon Plc $ICLR

Financiere des Professionnels Fonds d investissement inc. trimmed its stake in shares of Icon Plc (NASDAQ:ICLR) by 39.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,343 shares of the medical research company’s stock after selling 18,948 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.’s holdings in Icon were worth $5,347,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Toth Financial Advisory Corp bought a new position in Icon during the fourth quarter worth $27,000. Ameriflex Group Inc. bought a new position in Icon during the third quarter worth $33,000. Johnson Financial Group Inc. bought a new position in Icon during the third quarter worth $71,000. Quadrant Capital Group LLC bought a new position in Icon during the third quarter worth $78,000. Finally, Geneos Wealth Management Inc. boosted its position in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares during the period. 95.61% of the stock is owned by institutional investors.

Icon Trading Down 4.8%

ICLR opened at $144.59 on Thursday. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a 50-day simple moving average of $120.28 and a 200 day simple moving average of $140.53. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $11.07 billion, a price-to-earnings ratio of 23.47, a P/E/G ratio of 11.99 and a beta of 1.26.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, June 10th. The medical research company reported $2.52 earnings per share for the quarter, topping the consensus estimate of $2.47 by $0.05. Icon had a net margin of 5.98% and a return on equity of 9.50%. The business had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $1.99 billion. During the same quarter in the prior year, the business posted $3.43 earnings per share. Icon’s revenue was up 2.5% compared to the same quarter last year. Analysts predict that Icon Plc will post 9.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ICLR. TD Cowen lifted their price objective on shares of Icon from $120.00 to $164.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Robert W. Baird set a $119.00 price objective on shares of Icon in a research report on Friday, February 13th. JPMorgan Chase & Co. lifted their price objective on shares of Icon from $120.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, May 29th. Truist Financial upped their price target on shares of Icon from $139.00 to $159.00 and gave the company a “hold” rating in a research note on Friday, May 29th. Finally, Weiss Ratings downgraded shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, May 29th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $156.44.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.